FINWIRES · TerminalLIVE
FINWIRES

Morgan Stanley Downgrades Vertex Pharmaceuticals to Equalweight From Overweight, Adjusts PT to $15 From $19

By

Vertex Pharmaceuticals (VRTX) has an average rating of overweight and mean price target of $558.17, according to analysts polled by FactSet.

What else is happening in Research?